zeleciment rostudirsen
z-rostudirsen · DYNE-251 Nucleic Acid Target: TfR1, dystrophin exon 51, dystrophin, exon 51
Dyne Therapeutics, Inc.
Most recent annual filing: 2026-03-02
Pipeline (10 active programs)
zeleciment basivarsen
DYNE-101 · z-basivarsen Nucleic Acid Target: TfR1, DMPK, DMPK RNA
DYNE-302
Nucleic Acid Target: TfR1, DUX4
DYNE-401
DYNE-253
Nucleic Acid Target: TfR1, dystrophin exon 53, exon 53
DYNE-245
Nucleic Acid Target: TfR1, dystrophin exon 45, exon 45
DYNE-244
Nucleic Acid Target: TfR1, dystrophin exon 44, exon 44
DYNE-255
Nucleic Acid Target: TfR1, dystrophin exon 55, exon 55
Conjugate 1
Nucleic Acid Target: MAPT
- Undisclosed indication
Conjugate 2
Nucleic Acid Target: MAPT
- Undisclosed indication
Technology platforms
FORCE
TfR1-targeting Fab-conjugate delivery platform that links therapeutic payloads (PMOs, ASOs, siRNAs, enzymes) to a proprietary anti-TfR1 Fab via a clinically-validated linker, enabling targeted delivery to skeletal, cardiac and smooth muscle and CNS. Disease focus: neuromuscular diseases including DMD, DM1, FSHD, Pompe disease, rare skeletal muscle diseases, and cardiac/metabolic muscle diseases.
Targets: TfR1, transferrin receptor 1
Biotech Distilled coverage (4)
- 2026-03-14 UPDATE: Dyne Therapeutics (DYN) - Generational Moment 🔒 Paid
- 2026-03-07 UPDATE: Dyne Therapeutics (DYN) - Annual Audit 🔒 Paid
- 2026-01-22 UPDATE: Dyne Secures Japan Orphan Drug Designation (ODD) 🔒 Paid
- 2026-01-20 Dyne Therapeutics (DYN): Scientific Due Diligence for FORCE™ and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.